MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Baxter International Accounts Receivables 2011-2025 | BAX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Baxter International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.54 B | 1.54 B | 2.34 B | 2.4 B | 1.7 B | 1.8 B | 1.7 B | 1.79 B | 1.69 B | 1.73 B | 2.8 B | 2.91 B | 2.42 B | 2.42 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.91 B | 1.54 B | 2.06 B |
Quarterly Accounts Receivables Baxter International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 B | 1.62 B | 1.49 B | 1.54 B | 2.37 B | 2.26 B | 2.28 B | 2.27 B | 2.3 B | 2.34 B | 2.3 B | - | 2.3 B | 2.4 B | 1.8 B | 1.8 B | 1.6 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.69 B | 1.69 B | 1.69 B | 1.69 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 1.88 B | 1.88 B | 2.8 B | 2.8 B | 2.91 B | 2.91 B | 2.91 B | 2.91 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.35 B | 2.49 B | 2.4 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.91 B | 1.49 B | 2.04 B |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
9.17 M | $ 24.56 | 0.7 % | $ 1.13 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 200.48 | -0.23 % | $ 57.7 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.24 M | $ 4.68 | 0.21 % | $ 94.4 M | USA |
 |
Harvard Bioscience
HBIO
|
16.1 M | $ 0.71 | -4.45 % | $ 30.1 M | USA |
 |
ICU Medical
ICUI
|
183 M | $ 148.28 | -0.1 % | $ 3.62 B | USA |
 |
iRhythm Technologies
IRTC
|
79.9 M | $ 170.21 | 0.82 % | $ 5.31 B | USA |
 |
AtriCure
ATRC
|
60.3 M | $ 41.07 | -3.09 % | $ 1.93 B | USA |
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
717 K | $ 4.85 | 2.11 % | $ 26.7 K | USA |
 |
Repro Med Systems
KRMD
|
4.05 M | $ 5.8 | 0.35 % | $ 264 M | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 13.42 | 2.13 % | $ 548 M | USA |
 |
The Cooper Companies
COO
|
829 M | $ 81.36 | -0.88 % | $ 16.2 B | USA |
 |
LeMaitre Vascular
LMAT
|
30.1 M | $ 83.04 | -1.14 % | $ 1.86 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 111.73 | 2.6 % | $ 5.41 B | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 137.35 | -0.72 % | $ 7.32 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 80.24 | -3.89 % | $ 4.04 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 9.22 | -0.27 % | $ 190 M | USA |
 |
Merit Medical Systems
MMSI
|
190 M | $ 86.49 | -0.24 % | $ 5.04 B | USA |
 |
Isoray
ISR
|
116 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.23 B | $ 559.7 | 3.2 % | $ 199 B | USA |
 |
OraSure Technologies
OSUR
|
23.8 M | $ 2.49 | - | $ 185 M | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.23 | -7.65 % | $ 22.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
475 K | $ 0.36 | -7.4 % | $ 28.7 M | USA |
 |
Nephros
NEPH
|
1.5 M | $ 4.98 | -0.8 % | $ 51.7 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
576 M | $ 251.67 | -0.27 % | $ 36.8 B | USA |
 |
Envista Holdings Corporation
NVST
|
363 M | $ 22.07 | 0.46 % | $ 3.8 B | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 44.0 | 1.43 % | $ 145 M | USA |
 |
STAAR Surgical Company
STAA
|
77.9 M | $ 23.49 | -2.65 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 253.98 | 0.82 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
3.82 M | $ 2.35 | -1.05 % | $ 190 M | USA |
 |
Pulse Biosciences
PLSE
|
61 K | $ 14.04 | -1.4 % | $ 674 M | USA |
 |
Predictive Oncology
POAI
|
746 K | - | - | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 160.09 | 1.72 % | $ 8.92 M | USA |
 |
Utah Medical Products
UTMD
|
3.39 M | $ 57.54 | -0.96 % | $ 209 M | USA |
 |
Retractable Technologies
RVP
|
7.79 M | $ 0.84 | 1.99 % | $ 25.1 M | USA |
 |
Teleflex Incorporated
TFX
|
459 M | $ 126.88 | 0.17 % | $ 5.94 B | USA |
 |
West Pharmaceutical Services
WST
|
552 M | $ 271.82 | 1.6 % | $ 19.8 B | USA |